{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T11:18:29Z","timestamp":1783077509031,"version":"3.54.6"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["GPP 2022"],"award-info":[{"award-number":["GPP 2022"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.msard.2025.106382","type":"journal-article","created":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T16:25:32Z","timestamp":1741451132000},"page":"106382","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Immune response to influenza vaccine in patients with relapsing multiple sclerosis treated with ofatumumab: Results from an open-label, multicenter, phase 4 study"],"prefix":"10.1016","volume":"97","author":[{"given":"Brian","family":"Steingo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Subei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Riser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Gitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Stankiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Piccolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerri","family":"Wyse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Weinstock-Guttman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.msard.2025.106382_bib0001","doi-asserted-by":"crossref","first-page":"e1999","DOI":"10.1212\/WNL.0000000000010380","article-title":"Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study","volume":"95","author":"Bar-Or","year":"2020","journal-title":"Neurology."},{"key":"10.1016\/j.msard.2025.106382_bib0002","series-title":"Clinical Guidance for Influenza Vaccination","year":"2024"},{"key":"10.1016\/j.msard.2025.106382_bib0003","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1471-2288-10-18","article-title":"Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model","volume":"10","author":"Coudeville","year":"2010","journal-title":"BMC. Med. Res. Methodol."},{"issue":"2","key":"10.1016\/j.msard.2025.106382_bib0004","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s10875-012-9813-x","article-title":"Rituximab-treated patients have a poor response to influenza vaccination","volume":"33","author":"Eisenberg","year":"2013","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.msard.2025.106382_bib0005","series-title":"Kesimpta Summary of Product Characteristics","year":"2021"},{"issue":"13","key":"10.1016\/j.msard.2025.106382_bib0006","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1212\/WNL.0000000000008157","article-title":"Practice guideline update summary: vaccine-preventable infections and immunization in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","volume":"93","author":"Farez","year":"2019","journal-title":"Neurology."},{"issue":"1","key":"10.1016\/j.msard.2025.106382_bib0007","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","article-title":"Multiple sclerosis","volume":"4","author":"Filippi","year":"2018","journal-title":"Nat. Rev. Dis. Primers."},{"issue":"6","key":"10.1016\/j.msard.2025.106382_bib0008","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus Teriflunomide in Multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.msard.2025.106382_bib0009","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40265-021-01650-7","article-title":"Ofatumumab: a review in relapsing forms of multiple sclerosis","volume":"82","author":"Kang","year":"2022","journal-title":"Drugs"},{"issue":"22","key":"10.1016\/j.msard.2025.106382_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.05.049","article-title":"Immunogenicity of a seasonal influenza and a pneumococcal polysaccharide vaccine in multiple sclerosis patients under disease modifying therapies: a single-center prospective study","volume":"42","author":"Marantos","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.msard.2025.106382_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2023.122852","article-title":"Immunogenicity and safety of vaccines in multiple sclerosis: a systematic review and meta-analysis","volume":"456","author":"Marantos","year":"2024","journal-title":"J. Neurol. Sci."},{"issue":"2","key":"10.1016\/j.msard.2025.106382_bib0012","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/cns.13034","article-title":"Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease-modifying therapies","volume":"25","author":"Metze","year":"2019","journal-title":"CNS. Neurosci. Ther."},{"key":"10.1016\/j.msard.2025.106382_bib0013","unstructured":"Novartis, 2022. Kesimpta (ofatumumab) [package insert]."},{"issue":"8","key":"10.1016\/j.msard.2025.106382_bib0014","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1177\/1352458513513970","article-title":"Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study","volume":"20","author":"Olberg","year":"2014","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2025.106382_bib0015","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41541-021-00422-4","article-title":"Vaccine strain affects seroconversion after influenza vaccination in COPD patients and healthy older people","volume":"7","author":"Snape","year":"2022","journal-title":"NPJ. Vaccines."},{"issue":"12","key":"10.1016\/j.msard.2025.106382_bib0016","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.3390\/vaccines10122167","article-title":"Immune response to SARS-CoV-2 mRNA vaccines in an open-label multicenter study in participants with relapsing multiple sclerosis treated with ofatumumab","volume":"10","author":"Ziemssen","year":"2022","journal-title":"Vaccines. (Basel)"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825001245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825001245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T11:41:22Z","timestamp":1762602082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825001245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":16,"alternative-id":["S2211034825001245"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106382","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune response to influenza vaccine in patients with relapsing multiple sclerosis treated with ofatumumab: Results from an open-label, multicenter, phase 4 study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106382","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106382"}}